Weekly Companion News: January 27, 2025

January 2025
Covetrus unveils Covetrus Platform for veterinary clinics
The Covetrus Platform, unveiled prior to VMX 2025, is designed to optimize every touchpoint between veterinarian and pet owner, from pre-visit to post-appointment, according to the company. Key features include built-in processing, new AI capabilities, bidirectional integration with Zoetis Diagnostics and a suite of client-engagement tools. Meanwhile, the VetSuite practice improvement network is designed to address competitive pressures for independent practices.

 

Elanco says Credelio Quattro chewable tablets now available

Elanco Animal Health announced that Credelio Quattro (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) is now available for veterinarians to order at CredelioQuattroVet.com. Elanco says the monthly chewable tablet protects against six different types of parasites, including three intestinal worms that can be passed to humans: tapeworms, roundworms, hookworms, heartworms, ticks and fleas.

 

FDA seeks comments on innovation in animal health products

As part of its 2023 Animal and Veterinary Innovation Agenda, the FDA’s Center for Veterinary Medicine is exploring new or adapted regulatory approaches that may be needed to accommodate innovation in animal health products. Public comments are welcomed by Jan. 31 from animal food and drug industries, public health organizations, veterinarians, pet owners, ranchers and others.

 

Comments sought on veterinary technician educational standards

The AVMA Committee on Veterinary Technician Education and Activities will accept public comments no later than March 15, 2025, on proposed changes to educational standards for accredited veterinary technology education programs. The proposed changes involve standards related to skills and equipment.

 

Embrace Pet Insurance lists most common claims in 2024

Cleveland-based Embrace Pet Insurance has published 2024’s 10 most common claims: Allergic dermatitis ($182 average cost per claim), diarrhea ($224), osteoarthritis ($156), vomiting ($554), anxiety ($85), otitis externa ($204), skin mass ($580), lameness ($394), pruritis ($167) and cranial cruciate ligament tear ($1,447). Osteoarthritis claims saw the largest growth, increasing by 49% year-over-year.

 

Patterson announces expiration of 40-day ‘go shop’ period

Patterson Companies Inc. announced the expiration on Jan. 19 of the 40-day “go-shop” period under the terms of its previously announced agreement concerning its acquisition by Patient Square Capital. The agreement allowed Patterson and its representatives to actively solicit and consider alternative acquisition proposals from third parties during the “go-shop” period. Patterson did not receive any alternative acquisition proposals from any third party during the period.

 

Revelation Pharma launches animal health division

Revelation Pharma, a network of compounding pharmacies, will introduce its new animal-focused division – Revelation Animal Health – at VMX 2025. With main pharmacy hubs on both coasts and a growing network of pharmacies, Revelation Animal Health can partner with veterinarians nationwide, according to the firm. Future plans include animal dietary supplements, nationwide availability of wholesale items through Revelation Wholesale, and nationwide clinical consulting.

 

IDEXX Cancer Dx to be available in late March

IDEXX Laboratories, Inc. announced the launch of IDEXX Cancer Dx, a diagnostic panel with early detection of lymphoma in dogs, especially the 20 million dogs at higher risk for cancer in North America. IDEXX Cancer Dx can be added to panels for sick pets and integrated into annual wellness screenings for as low as $15, providing actionable results within two to three days, according to the company.

>